Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290)

BACKGROUND AND OBJECTIVES

In vitro and in vivo experimental data for fozivudine tidoxil [BM21.1290 (FZD) an ether-lipid conjugate of zidovudine] have shown better efficacy, no myelotoxicity and better tolerability compared with zidovudine. Therefore, the objectives of our study were to evaluate the safety of FZD in patients with human immunodeficiency virus (HIV) infection and to establish basic pharmacokinetic data.

PATIENTS AND METHODS

In a Phase I dose-escalating trial, seven different single dose applications were studied in 39 patients: 50, 100, 300, 600, 900, 1200 and 1800 mg in capsule and tablet formulations. Inclusion criteria were HIV infection, CD4 count > 100 cells/mm3 and informed consent. Exclusion criteria were active opportunistic manifestations, concomitant zidovudine therapy and neutropenia (< 750 neutrophils/mm3). Safety parameters, 24 h plasma levels and urinary excretion were determined.

RESULTS

The tolerance of FZD was excellent up to single doses of 1800 mg. In only one case, a single episode of loose stool was reproducible in a second treatment period and was therefore considered to be a probable drug-related event. In an amendment to the trial, a tablet formulation of FZD did not induce diarrhoea in this patient. FZD was available in measurable concentrations after 2 to 4 h. Maximum concentrations were reached after 4 to 8 h. After normalization for a dose of 100 mg/patient, the mean AUC was 8.6 mg x h/l and the mean Cmax was 1.13 mg/l; t1/2 was 3.78 h. Interestingly, plasma concentrations of zidovudine and zidovudine glucuronide were much lower than with equimolar zidovudine doses.

CONCLUSIONS

The zidovudine conjugate FZD is safe and well tolerated at the seven doses tested. Phase II trials are warranted.

Measurements of electroweak [Formula: see text] production and constraints on anomalous gauge couplings with the ATLAS detector

Measurements of the electroweak production of a W boson in association with two jets at high dijet invariant mass are performed using [Formula: see text] 7 and 8 [Formula: see text] proton-proton collision data produced by the Large Hadron Collider, corresponding respectively to 4.7 and 20.2 fb[Formula: see text] of integrated luminosity collected by the ATLAS detector. The measurements are sensitive to the production of a W boson via a triple-gauge-boson vertex and include both the fiducial and differential cross sections of the electroweak process.

Denis RD, Stabile A, Staerz S, Stahlman J, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark GH, Stark J, Staroba P, Starovoitov P, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tam JYC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teischinger FA, Teixeira-Dias P, Temming KK, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson RJ, Thompson AS, Thomsen LA, Thomson E, Thomson M, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turgeman D, Turra R, Turvey AJ, Tuts PM, Tyndel M, Ucchielli G, Ueda I, Ueno R, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valderanis C, Valdes Santurio E, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vazeille F, Vazquez Schroeder T, Veatch J, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vittori C, Vivarelli I, Vlachos S, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang T, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Wessels M, Wetter J, Whalen K, Whallon NL, Wharton AM, White A, White MJ, White R, White S, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wittkowski J, Wollstadt SJ, Wolter MW, Wolters H, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yuen SPY, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zeng JC, Zeng Q, Zengel K, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang R, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, zur Nedden M, Zurzolo G, Zwalinski L. Measurement of event-shape observables in [Formula: see text] events in pp collisions at [Formula: see text] [Formula: see text] with the ATLAS detector at the LHC

Event-shape observables measured using charged particles in inclusive Z-boson events are presented, using the electron and muon decay modes of the Z bosons. The measurements are based on an integrated luminosity of [Formula: see text] of proton-proton collisions recorded by the ATLAS detector at the LHC at a centre-of-mass energy [Formula: see text] [Formula: see text]. Charged-particle distributions, excluding the lepton-antilepton pair from the Z-boson decay, are measured in different ranges of transverse momentum of the Z boson. Distributions include multiplicity, scalar sum of transverse momenta, beam thrust, transverse thrust, spherocity, and [Formula: see text]-parameter, which are in particular sensitive to properties of the underlying event at small values of the Z-boson transverse momentum. The measured observables are compared with predictions from Pythia 8, Sherpa, and Herwig 7. Typically, all three Monte Carlo generators provide predictions that are in better agreement with the data at high Z-boson transverse momenta than at low Z-boson transverse momenta, and for the observables that are less sensitive to the number of charged particles in the event.

Search for triboson [Formula: see text] production in pp collisions at [Formula: see text] [Formula: see text] with the ATLAS detector

This paper reports a search for triboson [Formula: see text] production in two decay channels ([Formula: see text] and [Formula: see text] with [Formula: see text]) in proton-proton collision data corresponding to an integrated luminosity of 20.3 [Formula: see text] at a centre-of-mass energy of 8 [Formula: see text] with the ATLAS detector at the Large Hadron Collider. Events with exactly three charged leptons, or two leptons with the same electric charge in association with two jets, are selected. The total number of events observed in data is consistent with the Standard Model (SM) predictions. The observed 95% confidence level upper limit on the SM [Formula: see text] production cross section is found to be 730 fb with an expected limit of 560 fb in the absence of SM [Formula: see text] production. Limits are also set on WWWW anomalous quartic gauge couplings.

Panagiotopoulou E, Pandini CE, Panduro Vazquez JG, Pani P, Panitkin S, Pantea D, Paolozzi L, Papadopoulou TD, Papageorgiou K, Paramonov A, Paredes Hernandez D, Parker AJ, Parker MA, Parker KA, Parodi F, Parsons JA, Parzefall U, Pascuzzi VR, Pasqualucci E, Passaggio S, Pastore F, Pásztor G, Pataraia S, Pater JR, Pauly T, Pearce J, Pearson B, Pedersen LE, Pedersen M, Pedraza Lopez S, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penwell J, Peralva BS, Perego MM, Perepelitsa DV, Perez Codina E, Perini L, Pernegger H, Perrella S, Peschke R, Peshekhonov VD, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrolo E, Petrov M, Petrucci F, Pettersson NE, Peyaud A, Pezoa R, Phillips PW, Piacquadio G, Pianori E, Picazio A, Piccaro E, Piccinini M, Pickering MA, Piegaia R, Pilcher JE, Pilkington AD, Pin AWJ, Pinamonti M, Pinfold JL, Pingel A, Pires S, Pirumov H, Pitt M, Plazak L, Pleier MA, Pleskot V, Plotnikova E, Pluth D, Poettgen R, Poggioli L, Pohl D, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Pommès K, Pontecorvo L, Pope BG, Popeneciu GA, Poppleton A, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Potter CT, Poulard G, Poveda J, Pozdnyakov V, Pozo Astigarraga ME, Pralavorio P, Pranko A, Prell S, Price D, Price LE, Primavera M, Prince S, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Puddu D, Purohit M, Puzo P, Qian J, Qin G, Qin Y, Quadt A, Quayle WB, Queitsch-Maitland M, Quilty D, Raddum S, Radeka V, Radescu V, Radhakrishnan SK, Radloff P, Rados P, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Rammensee M, Rangel-Smith C, Ratti MG, Rauch DM, Rauscher F, Rave S, Ravenscroft T, Ravinovich I, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reed RG, Reeves K, Rehnisch L, Reichert J, Reiss A, Rembser C, Ren H, Rescigno M, Resconi S, Rezanova OL, Reznicek P, Rezvani R, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel CJ, Rieger J, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ristić B, Ritsch E, Riu I, Rizatdinova F, Rizvi E, Rizzi C, Roberts RT, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robson A, Roda C, Rodina Y, Rodriguez Perez A, Rodriguez Rodriguez D, Roe S, Rogan CS, Røhne O, Roloff J, Romaniouk A, Romano M, Romano Saez SM, Romero Adam E, Rompotis N, Ronzani M, Roos L, Ros E, Rosati S, Rosbach K, Rose P, Rosien NA, Rossetti V, Rossi E, Rossi LP, Rosten JHN, Rosten R, Rotaru M, Roth I, Rothberg J, Rousseau D, Rozanov A, Rozen Y, Ruan X, Rubbo F, Rudolph MS, Rühr F, Ruiz-Martinez A, Rurikova Z, Rusakovich NA, Ruschke A, Russell HL, Rutherfoord JP, Ruthmann N, Ryabov YF, Rybar M, Rybkin G, Ryu S, Ryzhov A, Rzehorz GF, Saavedra AF, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Saha P, Sahinsoy M, Saimpert M, Saito T, Sakamoto H, Sakurai Y, Salamanna G, Salamon A, Salazar Loyola JE, Salek D, Sales De Bruin PH, Salihagic D, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sammel D, Sampsonidis D, Sánchez J, Sanchez Martinez V, Sanchez Pineda A, Sandaker H, Sandbach RL, Sandhoff M, Sandoval C, Sankey DPC, Sannino M, Sansoni A, Santoni C, Santonico R, Santos H, Santoyo Castillo I, Sapp K, Sapronov A, Saraiva JG, Sarrazin B, Sasaki O, Sato K, Sauvan E, Savage G, Savard P, Savic N, Sawyer C, Sawyer L, Saxon J, Sbarra C, Sbrizzi A, Scanlon T, Scannicchio DA, Scarcella M, Scarfone V, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer L, Schaefer R, Schaeffer J, Schaepe S, Schaetzel S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Scharf V, Schegelsky VA, Scheirich D, Schernau M, Schiavi C, Schier S, Schillo C, Schioppa M, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schneider B, Schnoor U, Schoeffel L, Schoening A, Schoenrock BD, Schopf E, Schott M, Schouwenberg JFP, Schovancova J, Schramm S, Schreyer M, Schuh N, Schulte A, Schultens MJ, Schultz-Coulon HC, Schulz H, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schweiger H, Schwemling P, Schwienhorst R, Schwindling J, Schwindt T, Sciolla G, Scuri F, Scutti F, Searcy J, Seema P, Seidel SC, Seiden A, Seifert F, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Seliverstov DM, Semprini-Cesari N, Serfon C, Serin L, Serkin L, Sessa M, Seuster R, Severini H, Sfiligoj T, Sforza F, Sfyrla A, Shabalina E, Shaikh NW, Shan LY, Shang R, Shank JT, Shapiro M, Shatalov PB, Shaw K, Shaw SM, Shcherbakova A, Shehu CY, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimojima M, Shirabe S, Shiyakova M, Shmeleva A, Shoaleh Saadi D, Shochet MJ, Shojaii S, Shope DR, Shrestha S, Shulga E, Shupe MA, Sicho P, Sickles AM, Sidebo PE, Sideras Haddad E, Sidiropoulou O, Sidorov D, Sidoti A, Siegert F, Sijacki D, Silva J, Silverstein SB, Simak V, Simic L, Simion S, Simioni E, Simmons B, Simon D, Simon M, Sinervo P, Sinev NB, Sioli M, Siragusa G, Siral I, Sivoklokov SY, Sjölin J, Skinner MB, Skottowe HP, Skubic P, Slater M, Slavicek T, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smestad L, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith JW, Smith MNK, Smith RW, Smizanska M, Smolek K, Snesarev AA, Snyder IM, Snyder S, Sobie R, Socher F, Soffer A, Soh DA, Sokhrannyi G, Solans Sanchez CA, Solar M, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Song HY, Sood A, Sopczak A, Sopko V, Sorin V, Sosa D, Sotiropoulou CL, Soualah R, Soukharev AM, South D, Sowden BC, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spettel F, Spighi R, Spigo G, Spiller LA, Spousta M, St. Denis RD, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark GH, Stark J, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teischinger FA, Teixeira-Dias P, Temming KK, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Tupputi SA, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Valderanis C, Valdes Santurio E, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Ferrer JAV, Van Den Wollenberg W, Van Der Deijl PC, van der Graaf H, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vasquez GA, Vazeille F, Schroeder TV, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Boeriu OEV, Viehhauser GHA, Viel S, Vigani L, Villa M, Perez MV, Vilucchi E, Vincter MG, Vinogradov VB, Vittori C, Vivarelli I, Vlachos S, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Milosavljevic MV, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang W, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Weber SA, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Wetter J, Whalen K, Whallon NL, Wharton AM, White A, White MJ, White R, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wolf TMH, Wolff R, Wolter MW, Wolters H, Worm SD, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xu D, Xu L, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Wong KHY, Ye J, Ye S, Yeletskikh I, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yuen SPY, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zeng JC, Zeng Q, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang R, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou M, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, Nedden MZ, Zwalinski L. Measurement of jet activity produced in top-quark events with an electron, a muon and two b-tagged jets in the final state in pp collisions at [Formula: see text] TeV with the ATLAS detector

Measurements of jet activity in top-quark pair events produced in proton-proton collisions are presented, using 3.2 fb[Formula: see text] of pp collision data at a centre-of-mass energy of 13 TeV collected by the ATLAS experiment at the Large Hadron Collider. Events are chosen by requiring an opposite-charge [Formula: see text] pair and two b-tagged jets in the final state. The normalised differential cross-sections of top-quark pair production are presented as functions of additional-jet multiplicity and transverse momentum, [Formula: see text]. The fraction of signal events that do not contain additional jet activity in a given rapidity region, the gap fraction, is measured as a function of the [Formula: see text] threshold for additional jets, and is also presented for different invariant mass regions of the [Formula: see text] system. All measurements are corrected for detector effects and presented as particle-level distributions compared to predictions with different theoretical approaches for QCD radiation. While the kinematics of the jets from top-quark decays are described well, the generators show differing levels of agreement with the measurements of observables that depend on the production of additional jets.

Inhibition of human tumor colony formation by the new alkyl lysophospholipid ilmofosine

The cytostatic-cytotoxic effect of the new thioether alkyl lysophospholipid analogue Ilmofosine (1-hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine, BM 41.440) on colony formation of 30 different spontaneous human tumors was investigated in vitro with the use of a methylcellulose monolayer assay. Twenty-five neoplasms were sensitive to Ilmofosine within the concentration range tested (0-16 micrograms/ml). The most susceptible tumors were 2 colon carcinomas, 2 squamous cell carcinomas and 1 small-cell carcinoma of the lungs, 2 myosarcomas, 2 ovarian carcinomas, 1 gallbladder carcinoma, and 1 pleural mesothelioma with 50% colony formation inhibition doses ranging from 1.5 to 4.0 micrograms/ml. Due to the sensitivity criteria of the U.S. National Cancer Institute (greater than or equal to 70% inhibition of colony formation at 10 micrograms/ml), 15 of 30 tumors tested have to be considered as susceptible to Ilmofosine.

Prompt and non-prompt J / ψ elliptic flow in Pb+Pb collisions at s NN = 5.02 Tev with the ATLAS detector

The elliptic flow of prompt and non-prompt J / ψ was measured in the dimuon decay channel in Pb+Pb collisions ats NN = 5.02   TeV with an integrated luminosity of 0.42 nb - 1 with the ATLAS detector at the LHC. The prompt and non-prompt signals are separated using a two-dimensional simultaneous fit of the invariant mass and pseudo-proper decay time of the dimuon system from the J / ψ decay. The measurement is performed in the kinematic range of dimuon transverse momentum and rapidity 9 < p T < 30   GeV , | y | < 2 , and 0-60% collision centrality. The elliptic flow coefficient, v 2 , is evaluated relative to the event plane and the results are presented as a function of transverse momentum, rapidity and centrality. It is found that prompt and non-prompt J / ψ mesons have non-zero elliptic flow. Prompt J / ψ v 2 decreases as a function of p T , while for non-prompt J / ψ it is, with limited statistical significance, consistent with a flat behaviour over the studied kinematic region. There is no observed dependence on rapidity or centrality.

Efficacy and tolerability of picumast dihydrochloride in comparison with placebo in asthmatic patients

In a randomized double-blind study, 107 patients with extrinisic, intrinsic or mixed bronchial asthma and impaired lung function received either picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarin dihydrochloride) 1 mg or placebo twice daily for 6 weeks after a 2-week placebo phase. Patients given picumast dihydrochloride demonstrated significant improvements compared with baseline in morning and evening peak flow and asthmatic symptoms like morning tightness, cough, dyspnoea, obstruction, number of asthma attacks during night and day, sum of asthmatic symptom scores, in vital capacity and Tiffeneau index, and a significant reduction of inhaled adjuvant medications. In contrast, placebo recipients improved significantly only in daytime asthma attacks, obstruction, sum of symptom scores, and Tiffeneau index. The differences between the picumast dihydrochloride and placebo groups significantly favoured picumast dihydrochloride for improvements in mean number of daytime asthma attacks, morning tightness, aerosol use and sum of symptom scores. Adverse reactions were minor and infrequent; no tiredness occurred with picumast dihydrochloride. Tolerability of both picumast dihydrochloride and placebo was rated as "good" to "very good" by patients and physicians.

[Utilization of maltose during shorttime parenteral nutrition (author's transl)]

Twelve metabolically healthy patients, who had to undergo cholecystectomy or gastric resection, were fed intermittently by the parenteral route (via veins of the upper limbs) post-operatively up to and including the 2nd post-operative day with a combined maltose-glucose solution in parallel with an 8% mixture of crystalline L-aminoacids. At an administration rate of 150 g maltose/day and 250 g glucose/day with the simultaneous administration of 80 g aminoacids, the mean carbohydrate utilisation was 82,5%. The glucose and maltose levels in the blood fluctuated in accordance with the infusion periods and the free fatty acids levels measured were their mirror image. On the whole free fatty acids were lowered significantly, which indicates adequate carbohydrate supply with consequent inhibition of lipolysis. The degree of tolerance was determined objectively by measurement of the acid-base parameter, gamma-GT, alkaline phosphatase, GOT, bilirubin, uric acid, creatinine and serum electrolytes. No changes were found which could be attributed to the administration of the infusion solution.